Omalizumab rescued a asthma-copd overlap syndrome patient from a status asthmatics under the icu management.
OMALIZUMAB RESCUED A ASTHMA-COPD OVERLAP SYNDROME PATIENT FROM A STATUS ASTHMATICS UNDER THE ICU MANAGEMENT. Arerugi. 2016 Jul;65(7):937-41 Authors: Gamo S, Iijima H, Seki Y, Horaguchi R, Suda Y, Shindoh Y Abstract An atopic asthmatic of 65-year-old man who was complicated with COPD and treated with inhaled corticosteroid, long-acting β2 agonist, long-acting muscarinic antagonist, and leukotriene receptor antagonist was hospitalized with a severe asthmatic attack. He was intubated and went onto an artificial respirator. He was gradually relieved by repeated intravenous administration of high-dose corticosteroid, and a respirator was switched over to non-invasive positive pressure ventilation on 24th day. However, he repeated asthmatic attacks which needed corticosteroid to recover. Omalizumab was administered on 35th day and asthmatic attacks remarkably decreased. He left the hospital on 71st day. It was thought that the additional administration of omalizumab provided a good clinical response for an intractable asthma. PMID: 27545060 [PubMed - in process]
Inhaled corticosteroid (ICS)–based therapy is often used for patients with chronic obstructive pulmonary disease (COPD). However, this approach is under scrutiny because of ICS overuse in patients for whom it is not recommended and because of concerns about adverse events, particularly pneumonia, with long-term ICS use. Evidence suggests ICS may be beneficial in specific patients, namely, those with high blood eosinophil counts (eg, ≥300 cells/µL) or who are at a high risk of exacerbations. According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020 ABCD assessment tool, these patient...
CONCLUSION: At least in the setting of this mail order pharmacy duplicate (i. e. contraindicated and potentially dangerous) prescriptions are relatively rare. Prescribers and pharmacists should be aware of the issue of duplicates - especially when prescribing or filling prescriptions with combination products. PMID: 32143230 [PubMed - as supplied by publisher]
CONCLUSIONS: Despite enhanced education on asthma self-management in China during recent years, few patients were using daily controller medications before the onset of their exacerbation, indicating that more educational efforts and considerations are needed. The findings of this study may improve our understanding of hospital admission for asthma exacerbation in mainland China and provide evidence for decision-making. PMID: 32141261 [PubMed]
ConclusionOur findings do not support an increased risk of major osteoporotic fracture in older women with chronic respiratory diseases due to long-term ICS use.
CONCLUSION: Post-addition of BUD inhibited the virus-induced TSLP and CCL26 from the airway epithelial cells. These results suggest that inhalation of BUD after viral infection has beneficial effects on asthma. CONCLUSION: Late addition of BUD may benefit among patient with viral infection and type 2 allergic airway disease such as asthma. PMID: 32120846 [PubMed - in process]
ConclusionsThese findings suggest that glycopyrronium, formoterol, and a combination of glycopyrronium, formoterol, and budesonide inhibit HCoV-229E replication partly by inhibiting receptor expression and/or endosomal function and that these drugs modulate infection-induced inflammation in the airway.
ConclusionsThis large observational study based on claims data reliably identified subjects with COPD treated with open TT and their burden on the NHS. Moreover, it could describe the real clinical management of the open TT, before the marketing of the fixed one. These findings are useful for health policymakers in order to promote the appropriate utilization of both currently marketed and future therapies.
Conclusions Inhaled corticosteroid use is not associated with a reduction in lung cancer incidence in patients with COPD. Observational studies reporting such reduction may have been affected by time-related biases and the inclusion of patients with asthma. The proposition of a randomised trial warrants some caution.
Theophylline is still one of the most widely prescribed drugs for the treatment of asthma and COPD in developing countries because the majority of asthma and COPD medicines and are largely unavailable and also because it is a cheaper option. In any case, its anti-inflammatory effects and capacity to reverse corticosteroid resistance deserve consideration, but it can induce numerous side effects and drug-drug interactions and frequently requires measurement of drug levels in plasma. In order to overcome the problems posed by theophylline, other xanthines have been developed.
Studies have demonstrated association of inhaled corticosteroids (ICS) with risk of pneumonia in chronic obstructive pulmonary disease patients. Risk in asthmatic children on ICS remains unclear. Our aim was to determine the association of ICS use with pneumonia risk in asthmatic children.